Home » News » News » CIRM Seeks to Protect Exclusivity for Biosimilars
CIRM Seeks to Protect Exclusivity for Biosimilars
Submitted on:
01.25.2010
The Governing Board of the California Institute for Regenerative Medicine (CIRM) is calling for preserving protections for biosimilars in healthcare reform legislation. In a Jan. 19 letter, CIRM asked President Obama and Congress to establish a data exclusivity period that allows small and emerging companies at the vanguard of this field to recoup the massive investment required. Without a predictable 12-year data exclusivity period for stem cell research and development, patient access to this promising technology will be delayed or eliminated and California’s biotechnology sector will suffer. CIRM's singular focus is bringing therapies and cures to patients around the nation as quickly as possible. The board unanimously voted in favor of Congresswoman Anna Eshoo’s pathway for biosimilars, which included a 12-year period of data exclusivity. To read the letter, click here.
CHI-Advancing California Biomedical Research and Innovation
Back to News Items